Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
Ping-Chih HsuJohn Wen-Cheng ChangChing-Fu ChangChen-Yang HuangCheng-Ta YangChih-Hsi Scott KuoYueh-Fu FangChiao-En WuPublished in: Therapeutic advances in respiratory disease (2022)
This study demonstrated the efficacy of first-line EGFR-TKIs and sequential osimertinib therapy. The results of our study suggest that T790M mutation tests are important for the use of subsequent osimertinib, which yielded favorable survival outcomes.